{"DataElement":{"publicId":"3131993","version":"1","preferredName":"Metastatic Breast Carcinoma Progesterone Receptor Detection Method Text","preferredDefinition":"The free-text field to specify the method of measurement used to detect the status of the progesterone receptor (PR) in a sample of metastatic breast carcinoma, e.g., dextran coated charcoal.","longName":"3131991v1.0:2018274v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3131991","version":"1","preferredName":"Metastatic Breast Carcinoma Positive Finding Progesterone Receptor Other Scale Measurement","preferredDefinition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002_An observation confirming something, such as the presence of a disease, condition, or microorganism._._Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives._Different than the one(s) previously specified or mentioned._An ordered reference standard used to measure incremental changes._Measurement; the size or magnitude of something.","longName":"3131989v1.0:3086845v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3131989","version":"1","preferredName":"Positive Finding Metastatic Breast Carcinoma Progesterone Receptor","preferredDefinition":"An observation confirming something, such as the presence of a disease, condition, or microorganism.:(MET-uh-STAT-ik) Having to do with metastasis, which is the spread of cancer from one part of the body to another.:A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.","longName":"C38758:C14174:C4872:C17075","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progesterone Receptor","conceptCode":"C17075","definition":"Progesterone receptor (933 aa, ~99 kDa) is encoded by the human PGR gene. This protein is involved in the regulation of transcription.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E93E677-3E9D-3E06-E040-BB89AD434760","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3086845","version":"1","preferredName":"Other Scale Measurement","preferredDefinition":"Different than the one(s) previously specified or mentioned.:an ordered reference standard.:Measurement; the size or magnitude of something.","longName":"C17649:C25664:C25209","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Scale","conceptCode":"C25664","definition":"An ordered reference standard used to measure incremental changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Measurement","conceptCode":"C25209","definition":"Annotation used to indicate the size or magnitude of something that was determined by comparison to a standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D0321B-CB79-D063-E040-BB89AD437607","latestVersionIndicator":"Yes","beginDate":"2010-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-17","modifiedBy":"ONEDATA","dateModified":"2010-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E93E677-3EAB-3E06-E040-BB89AD434760","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018274","version":"1","preferredName":"Diagnosis Text","preferredDefinition":"the free text field to specify the diagnosis.","longName":"DX_TXT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184342","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"Text","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2103-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2055B67-4F83-69AE-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"CAMPBELB","dateModified":"2004-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787500","version":"1","longName":"BRCA","context":"NCIP"}]}],"AlternateNames":[{"name":"metastatic_breast_carcinoma_progesterone_receptor_detection_method_text","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"Define method of calculation","type":"Preferred Question Text","description":"Define method of calculation for PR positivity (Metastatic)","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E93E677-3EE8-3E06-E040-BB89AD434760","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-24","modifiedBy":"TSESU","dateModified":"2018-07-12","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) per request of T. Lichtenberg 8/2010","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}